A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers.

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2012

At a glance

  • Drugs VB 201 (Primary)
  • Indications Atherosclerosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 13 Jun 2012 New source identified and integrated: European Clinical Trials Database record EudraCT2010-020783-38.
    • 15 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top